@peptidepirate theoretical innate-immunity stack: Ta-1 + Ta-2 + LL-37 + Glutathione + NAD+
Hantavirus and peptides 🏴☠️ Coming back with the peptide stack that in "theory" could maximize innate immunity🏴☠️ The clear winners (based off feedback from community )🗞️ Ta-1 Ta-2 LL-37 Glutathione NAD+ 🧬🔬
A 'theoretical' community-curated immunity stack with appropriately humble framing. The compounds are directionally right: Ta-1 has FDA orphan status and EU approval, LL-37 is the most-studied antimicrobial peptide, glutathione and NAD cover antioxidant bases. Three issues. 'Ta-2' is ambiguous; thymosin alpha-2 is real but obscure and may not be what the author meant. No doses are listed. And for actual hantavirus exposure, standard precautions (rodent-excrement avoidance, respirator when cleaning enclosed spaces) outperform any peptide protocol by orders of magnitude.
| Goal | Score | Grade | Weight | Why |
|---|---|---|---|---|
| Longevity | 72 | C- | 55% | Ta-1 + glutathione + NAD have legitimate immune-aging and antioxidant mechanisms; the closest mapping for an 'innate immunity' framing in the standard goal axes. 'Theoretical' framing acknowledges the human RCT base is thin. |
| Cognition | — | Not targeted | — | No ingredient with a primary cognitive mechanism. |
| Sleep & recovery | 70 | C- | 25% | Recovery axis interpreted broadly to capture immune-resilience and recovery from acute illness, which is the author's actual framing. The standard sleep_recovery rubric doesn't quite fit, but it's the closest secondary axis. |
| Energy & metabolism | 70 | C- | 20% | NAD precursors have plausible mitochondrial mechanism; glutathione is the master antioxidant supporting mitochondrial function. Both are legitimate but neither is metabolically targeted in the way the author frames the stack. |
| Body recomposition | — | Not targeted | — | Stack isn't framed for body composition; no anabolic agent or training stimulus. |
Ingredients (5)
Thymosin Alpha-1
Thymosin Alpha-1 on peptidelist.org ↗
- Dose
- unspecified
- Mechanism
- Synthetic version of a thymic-derived 28-amino-acid peptide. Immunomodulator with FDA orphan-drug status for some indications and EU approval for chronic hepatitis B. Modulates T-cell maturation and innate immune function.
- Take
- The most-evidence-backed compound in the stack. Subcutaneous use at 1.6mg twice weekly is the published HBV protocol; longevity and general-immune protocols vary widely. For an innate-immunity stack with theoretical framing, Ta-1 is the right primary anchor. Author doesn't specify dose, which matters for sustained vs acute use.
Thymosin Alpha-2
- Dose
- unspecified
- Mechanism
- Thymic peptide fragment with limited published characterization. Proposed immune-modulatory effects similar in class to Ta-1 but with thinner evidence base and no regulatory approvals.
- Take
- 'Ta-2' is ambiguous as written. Thymosin alpha-2 is a real but obscure thymic peptide fragment with limited research base outside immunology literature. The peptide-enthusiast community more often references Thymosin Beta-4 fragments (TB-500) or Thymalin/Thymopentin, neither of which is 'Ta-2.' Possible the author means a vendor-specific designation; without clarification, it's not clear what's actually in this slot.
LL-37
- Dose
- unspecified
- Mechanism
- 37-amino-acid antimicrobial peptide derived from cathelicidin. Direct membrane disruption of bacteria, viruses, and fungi; immunomodulatory effects on innate immune cells; supports vitamin-D-axis-mediated immune function.
- Take
- LL-37 (cathelicidin antimicrobial peptide) has the strongest preclinical antimicrobial profile of any human-derived peptide. Some early-phase clinical work in topical wound infections and respiratory conditions. Subcutaneous or systemic use for innate immunity is less characterized; pharmacokinetics depend heavily on route. Author doesn't specify dose or route.
Glutathione
Glutathione on peptidelist.org ↗
- Dose
- unspecified
- Mechanism
- Tripeptide (glutamate-cysteine-glycine) and the body's primary endogenous intracellular antioxidant. Substrate for glutathione peroxidase and key in phase II liver detoxification.
- Take
- The master endogenous antioxidant. Oral bioavailability of reduced glutathione is poor; intracellular synthesis is gated by cysteine availability, which is why NAC (N-acetyl cysteine, a cysteine donor) is the supplement with the better evidence base. IV glutathione has its own evidence in some indications. Liposomal oral formulations are intermediate. Author doesn't specify form or dose, which determines whether this is delivering meaningfully or not.
NAD+
- Dose
- unspecified
- Mechanism
- NAD+ is a coenzyme central to mitochondrial energy production and sirtuin/PARP enzyme activity; declines with age. Supplemented as IV NAD+, oral NMN/NR precursors, or subcutaneous NAD+.
- Take
- Same vagueness problem NAD always has. Could mean IV NAD ($300-1500/session, weak evidence), oral NMN/NR precursors at 500-1000mg/day (weaker biomarker evidence, much lower cost), or subQ NAD. The choice has wildly different cost-effectiveness profiles. As an innate-immunity adjunct, NAD's mechanism is indirect (sirtuin/PARP and mitochondrial function); it's not a top-tier immunity intervention.
Risks & interactions
- Peptide stacks don't substitute for hantavirus exposure precautionshigh
The framing connects this peptide stack to hantavirus, but for actual exposure scenarios the highest-leverage interventions are public-health basics: don't sweep dry rodent droppings, ventilate enclosed spaces before cleaning, wear an N95 or better respirator, and seek medical attention immediately for fever or respiratory symptoms in the 1-6 weeks after potential exposure. HPS has ~38% mortality and is treatable only with supportive care. No peptide stack at any dose compensates for inhaled aerosolized virus. The stack as immune-resilience supplementation is fine; the stack as hantavirus prevention is a category error.
- 'Ta-2' is ambiguous as writtenmedium
Thymosin alpha-2 is a real but obscure peptide fragment with limited published research outside immunology literature. The peptide-enthusiast community typically references Ta-1, TB-500 (Thymosin Beta-4 fragment), or Thymalin/Thymopentin, none of which are 'Ta-2.' The author may mean a vendor-specific designation, a typo for one of the more common variants, or genuinely the obscure Ta-2. Without clarification, readers can't replicate.
- Oral glutathione bioavailabilitylow
Reduced glutathione has poor oral bioavailability. NAC (N-acetyl cysteine) at 600-1200mg/day has the better evidence base for raising endogenous glutathione, and IV glutathione is the route with most clinical use. Liposomal oral formulations are intermediate. Author doesn't specify form, which determines whether this is doing what it's supposed to.
- No doses listed across five ingredientslow
Standard 'community-curated theoretical stack' problem: a list isn't a protocol. Without doses, readers can't replicate, compare to research-typical protocols, or evaluate against the immune outcomes claimed. The 'theory' framing in the author's post is honest about this; readers should treat the stack as a research starting point, not a prescription.
For acute hantavirus exposure, the highest-leverage interventions are public-health basics, not peptides. Don't sweep dry rodent droppings (aerosolizes virus), ventilate enclosed spaces before cleaning, wear an N95 or better respirator, and seek medical attention for fever or respiratory symptoms in the 1-6 weeks after exposure. HPS has ~38% mortality and is treatable only with supportive care. Peptide-class immune support is sensible for general immune-aging; substituting it for primary prevention is the category error this post risks encouraging.
Estimated cost
Research-vendor / compounding-pharmacy pricing for Ta-1 (~$80-150/mo at modest doses), Ta-2 (~$60-120/mo, varies by vendor and what's actually being sold), LL-37 (~$60-120/mo). Oral glutathione (liposomal) ~$30-60/mo, IV ~$200-400/session. NAD ranges $30-80/mo (oral NMN/NR) up to $1200+/mo (regular IV NAD).